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David B. Goldstein is Professor of
Genetics in the Galton Laboratory,
Department of Biology, at
University College London. His
training is in population genetics,
and his primary contributions have
been in assessing the medical and
evolutionary implications of human
genetic diversity. His work currently
focuses on pharmacogenetics, the
genetics of complex disease, and
human evolution. He received his
PhD from Stanford University in
1994 and moved to the UK in 1996.
What turned you on to biology
in the first place? The Pacific
Ocean, particularly scuba diving
and walking the rocky coasts.
Naturally, I now spend my time in
front of a computer in central
London working on
pharmacogenetics.
Do you have a favourite paper ?
Yes: Botstein et al. (1980).
‘Construction of a genetic linkage
map in man using restriction
fragment length polymorphisms.’
Am. J. Hum. Genet. 32, 314-331.
David Botstein and colleagues
‘reversed’ genetics by arguing that
it would be possible to build a
genetic map of polymorphic
markers in man and use it to
localise disease genes by
correlating disease status and
marker transmission in affected
families. By the time I caught up
with the paper, the train had long
since left the station. A first
generation map had already been
completed, a denser second-
generation map was being
finalised, and a number of disease
genes had been mapped by
linkage. But the full consequences
of this new approach for gene
identification had not percolated
through the parts of population
genetics I worked in. The Botstein
et al. paper hit me like a sledge-
hammer when I finally read it
almost 15 years after it appeared,
and I changed my research
direction immediately. What
impressed me most was their
vision that linkage maps would
fundamentally transform human
genetics by allowing systematic
gene mapping based on a gene’s
position rather than its
biochemical effects — what was
therefore for a while called reverse
genetics. For me, the vision was
irresistible. Today, attention is
shifting from the study of families
to the study of populations, in
which associations between
markers and phenotypes in
population samples are identified.
But the basic idea is the same.
What is the best advice you’ve
been given? Early on I was told to
find a scientific focus that played
to my strengths and avoided my
weaknesses: to find something
that matched my intellectual style
and working habits, instead of
trying to adapt to something
against the grain. Having plenty of
personality flaws, for me it was
particularly good advice. 
What advice would you give
someone starting out in
science? The usual. The most
consistent piece of advice you hear
from scientists to one another is to
do ‘what interests you’. It’s good
advice, but what I would really
emphasize is how hard it can be to
follow it. The way science works
today, many people have only a
narrow window of opportunity to
break in, and after that it can
become a Herculean task. So you
have to establish some sort of
reputation early, and this can
interfere with an open-minded
evaluation of what is interesting.
And even after becoming
established, the risk remains that,
in satisfying the requirements of a
career trajectory, you lose the
energy and perspective necessary
to see new opportunities. Keeping
yourself open to change is an
active process. You have to step
away from it all, both the
responsibilities and the rewards —
preferably at the beach of course
— and ask yourself, what is really
interesting here, or what is really
important? What do I really want to
be doing? And if it is somewhat
different from what you are doing
at the moment, then you need a
transition strategy. Even with the
new inter-disciplinary craze, you
cannot just bang in a grant on a
totally new area for you and expect
it to be funded. You have to find
bridges between what you are
doing and what you want to do.
But all that is technical strategy.
The important thing is to know
where you want to go. 
If you knew earlier what you
know now, would you still
pursue the same research path?
I am doing now exactly what I want
to be doing, but I can’t see that I
can take much credit for that. It
doesn’t seem to have much to do
with early career choices. Human
genetics has changed so rapidly it
would have been all but impossible
to make an informed choice early
in my career. It seems to me to
matter less what you focus on early
in your career, as long as you keep
your eyes open and have the guts
to chase what most interests you.
Professional science has incredible
inertia, locking people into their
specialities. It is hard to get grants
outside your area, and can even be
hard to publish. So it can be pretty
unnerving trying to change
direction or even just branch out.
But science changes so fast you
have to be willing to change with it,
or run the risk of getting stuck in an
eddy that is of little interest to
anyone, including yourself.
How would you compare doing
science in Britain and the US?
I am often challenged on why a
Californian native would choose to
do science in the UK, especially
with what everyone hears about
under-funding in the UK. Except
for the obvious difference in scale,
however, I think UK science
measures up well against the US.
Certainly the strong labs in the UK
are just as good as those in the
US, and despite impressions to
the contrary, they are generally as
well funded. The one big
difference is the financial
weakness of universities. The lack
of centrally administered
resources makes it much harder
for universities in the UK to foster
new interdisciplinary research
areas, and often forces labs to do
almost everything for themselves,
which can result in considerable
inefficiencies. For biomedical
research in the UK to remain
competitive, the financial health of
the major research universities will
need to be restored, somehow.
Do you enjoy the media work
that you do? Sometimes. I
recently woke up unusually early to
join a television discussion about
how genetics would influence
healthcare. The presenter kicked
off by asking me to clarify the
pronunciation of deoxyribonucleic
acid, and then promptly thanked
me for coming in. But when there
is time to develop an idea, I really
enjoy the challenge of finding a
way to explain and motivate what I
do without the technical jargon.
Like it or not, I do think that
scientists have an obligation to
explain themselves to the public,
who after all fund our work: it is not
only in the public’s interest, but it
can be very helpful to scientists as
well. Certainly for me, explaining
things in popular terms gives me a
much broader perspective on the
work that I do. 
What do you think is the biggest
challenge facing your field? The
big applied challenge in my area of
human genetics is learning how to
incorporate genetic information
into healthcare, both at the level of
genetically personalized
healthcare and in the earlier
stages of personalized lifestyle
choices. In human evolution, the
next major phase will be
identifying the genetic bases of
the traits that have been under
selection in our evolutionary
history. And, closing the circle, I
am convinced many of these traits
will prove to be of medical
relevance, especially in terms of
how people respond to drugs.
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Heterochronic
genes
Allison L. Abbott
What does the term
heterochronic mean?
Heterochronic refers to the
development of cells or tissues at
an abnormal time relative to other
unaffected events in an organism;
the latter can thus serve as
temporal landmarks. Mutations in
heterochronic genes cause certain
cells to adopt cell fates normally
associated with earlier or later
times in development.
Heterochronic genes therefore
regulate the timing and sequence
of developmental events in specific
cell lineages, and thereby
coordinate events throughout a
developing organism.
Why study heterochronic genes
in worms? The nematode
Caenorhabditis elegans provides a
particularly tractable model for
studying heterochronic genes,
owing to its relatively simple and
invariant cell lineages. In the four
larval stages of its post-embryonic
development, C. elegans cells
exhibit stage-specific patterns of
developmental events, such as cell
division and cell fate specification,
with each stage separated by a
molt. Importantly, neither larval
growth nor progression through
the molting cycle in the worm are
affected by known heterochronic
mutations, allowing developmental
events to be monitored relative to
these temporal landmarks.
So, is this just a strange worm
phenomenon? No. Heterochronic
genes have been reported in many
different organisms, including
Drosophila (hunchback, Krüppel,
pdm, castor) and several species
of plants, including Arabidopsis
(HASTY) and rice (mori1).
What do heterochronic genes do
in worms? One class of
heterochronic mutations results in
an early, or precocious, phenotype
in which many of the normal cell
fate decisions of a specific larval
stage are skipped and much of the
worm instead executes the
developmental program of a later
stage. Examples include mutations
in lin-14, lin-28 and lin-41. Worms
with such mutations express adult
cell fates when the animal is still
sexually immature (Figure 1).
Conversely, a second class of
mutations results in a delayed, or
Figure 1.
(A) Cartoon depiction of C. elegans development through the four larval stages (L1 to
L4) to the adult (Ad) in heterochronic mutants relative to wild type. The time axis is from
top to bottom. In lin-14(lf) mutants, the L1-specific developmental program is skipped
and the L2-specific program is executed earlier than in wild-type. In contrast, in lin-29(lf)
mutants, the L4-specific program is repeated and the adult program is not executed.
(B) Working model of genetic interactions in the C. elegans heterochronic gene
pathway. The positions of lin-42, lin-46 and lin-58 in the pathway are not yet known. 
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